Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 16 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
D-Wave Quantum Inc. (NYSE: QBTS) Expands Quantum Optimization Offerings to Accelerate Commercial Adoption
At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables…
-
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the…
-
Thumzup Media Corp. (NASDAQ: TZUP) Continues Building Its Client Base with Its Proprietary Tech for Ad Campaigns
Social media commerce is expected to grow to $821 billion in 2025[1], demonstrating its importance…